We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Symplicity Trial Fails to Meet Endpoints: Unexpected Blow to Tech, Parallel Review
Symplicity Trial Fails to Meet Endpoints: Unexpected Blow to Tech, Parallel Review
Medtronic’s Symplicity renal denervation system for the treatment of uncontrolled hypertension failed to meet a primary endpoint in its U.S. pivotal trial, putting a surprising halt on a technology that had been expected to be a major revenue driver.